MedTrace Logo

Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

NCT01848041 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-11-26

Study results available
· View outcomes & findings →

Summary

This is an exploratory, proof of concept study to evaluate the safety and efficacy of RVL-1201 dosed once or twice daily for 14 days compared to a placebo (vehicle) control in patients with ptosis.

Conditions

  • Blepharoptosis

Interventions

DRUG

RVL-1201

RVL-1201 0.1% Ophthalmic Solution

DRUG

RVL-1201 Vehicle Placebo

RVL-1201 Vehicle Placebo

Sponsors & Collaborators

  • RVL Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Chuck Slonim, MD · Oculos Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2014-01-31
Completion
2014-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01848041 on ClinicalTrials.gov